ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In 2020, Chia-Hwa Lee et al., using a CRISPR/Cas9 lentiviral vector to disrupt ABL1 in the human CML K562 cell line, demonstrated a reduced proliferation rate as a consequence of BCR/ABL1 disruption [103].